Nkarta, Inc.

What they do

Nkarta is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead pipeline program, NKX019, is a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of autoimmune diseases. The company's modular engineering platform starts with mature NK cells derived from healthy donors and engineers them with a targeting receptor, OX40 costimulatory domain, CD3 zeta signaling moiety, and membrane-bound IL-15. NKX019 is being studied in Phase 1/2 clinical trials (Ntrust-1 and Ntrust-2) across multiple autoimmune indications.

Revenue drivers

• Product sales — No products approved for sale; no revenue generated from product sales to date.
• Collaboration/licensing — No collaboration or licensing revenue reported in the provided financials; revenue was $0 for fiscal years 2024 and 2025.
• Grants or other — No material non-product revenue sources disclosed; historical revenue of $115,000 in 2019 is immaterial.

Recent performance

For the second quarter ended June 30, 2026, Nkarta reported a net loss of $40.4 million, or $0.54 per share, including non-cash charges of $11.8 million (share-based compensation, depreciation, and impairment of right-of-use assets and equipment). R&D expenses were $29.0 million and G&A expenses were $14.1 million for the quarter. Cash, cash equivalents, restricted cash, and investments totaled $243.2 million as of June 30, 2026. For fiscal year 2025, the company reported a net loss of $104.1 million and zero revenue; operating cash flow was negative $88.7 million. The company had no dividends paid in 2023-2025.

Strategy

Nkarta is prioritizing its lead program NKX019 for autoimmune diseases, having deprioritized oncology studies (NKX019 and NKX101) that closed enrollment in 2023. The company is advancing Ntrust-1 and Ntrust-2, Phase 1/2 dose-escalation trials across multiple autoimmune indications (lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, ANCA-associated vasculitis, and rheumatoid arthritis). Recent FDA agreements enable outpatient administration (reducing post-dose monitoring from 24 to 2 hours) and allow re-dosing, with enrollment at the 4 billion cells per dose level (12 billion cells total per cycle). The company is expanding into community-based sites to broaden patient access beyond academic centers.

Risks

• Clinical-stage, no approved products — Nkarta has no products approved for sale and has not generated any product revenue, with limited operating history since 2015.
• Substantial and continuing losses — The company has incurred significant net losses since inception (e.g., $104.1 million in 2025) and expects to continue incurring losses as it funds R&D.
• Dependence on NKX019 clinical success — The entire pipeline is concentrated on NKX019 for autoimmune diseases; failure or delay in Ntrust-1 or Ntrust-2 would materially harm the business.
• Need for additional capital — While current cash is expected to fund operations into 2029, future capital requirements may require additional financing, and the company faces the risk of dilution or inability to raise funds.

Outlook

Management plans to present initial clinical data from Ntrust-1 and Ntrust-2 at a medical conference in 2026. Enrollment continues across all indications at the 4 billion cell dose level, and outpatient dosing is underway at community-based sites. The company expects its current cash balance of $243.2 million (as of June 30, 2026) to fund operations into 2029. No revenue is expected in the near term from product sales.